UCB (OTCMKTS:UCBJF) Shares Up 20.1% – Here’s What Happened

UCB SA (OTCMKTS:UCBJF) shares were up 20.1% during mid-day trading on Thursday. The company traded as high as $285.75 and last traded at $285.75. 1 shares changed hands during mid-day trading, a decline of 100% from the average daily volume of 635 shares. The stock had previously closed at $237.84.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on UCBJF shares. Piper Sandler reissued a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Jefferies Financial Group raised shares of UCB to a “hold” rating in a report on Monday, August 3rd. Finally, Stephens reaffirmed an “overweight” rating on shares of UCB in a report on Wednesday. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

UCB Price Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The business has a 50-day moving average price of $248.93 and a two-hundred day moving average price of $275.54.

UCB Company Profile

UCB is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for people living with severe diseases. Its primary therapeutic areas are neurology and immunology, with research activities spanning conditions such as epilepsy, myasthenia gravis, Parkinson’s disease, psoriasis, psoriatic arthritis, axial spondyloarthritis and other immune-mediated disorders.

The company’s medicines include Bimzelx (bimekizumab), an immunology treatment; Cimzia (certolizumab pegol), used for several inflammatory conditions; and a portfolio of neurological therapies that includes Briviact (brivaracetam), Keppra (levetiracetam), Fintepla (fenfluramine) and Nayzilam (midazolam).